NIPTE

NIIMBL Announces $15.8M to Fund 14 New Biopharmaceutical Manufacturing Projects

Retrieved on: 
Tuesday, August 9, 2022
Agilent Technologies, Workforce development, NIST, Manufacturing USA, Universal integration platform, Industry, NIPTE, Solano Community College, National Institute, LLC, Duquesne University, Commerce, Massachusetts Institute of Technology, Workforce, Eli Lilly and Company, Government, Institute, North Carolina State University, National Institute of Standards and Technology, U.S. Department of Defense Strategy for Operating in Cyberspace, Company, Education, Bristol Myers Squibb, Rensselaer Polytechnic Institute, Merck & Co., Pfizer, Partnership, Awareness, Continuity, Upstream, University, University of Delaware, Pharmaceutics, U.S. Department of Commerce Office of Security, RNA transfection, Adoption, Fine chemical, Pharmaceutical industry, Genentech, Technology

These projects were selected to best align with key areas of focus identified by NIIMBL and which best align to address industry needs.

Key Points: 
  • These projects were selected to best align with key areas of focus identified by NIIMBL and which best align to address industry needs.
  • Project Call 5.2 also included several workforce development projects that provide a variety of opportunities to those interested in entering or developing skills within the biopharmaceutical manufacturing industry.
  • The NIIMBL community is comprised of more than 200 members from academia, industry, government, and non-profit organizations all sharing a common goal to advance biopharmaceutical manufacturing.
  • The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.

NIIMBL Announces $3M to Fund 6 New Biopharmaceutical Manufacturing Projects

Retrieved on: 
Tuesday, October 5, 2021
University, Manufacturing USA, Waters, Agilent Technologies, Partnership, U.S. Department of Commerce Office of Security, Global Health, North Carolina State University, PerkinElmer, Piaggio Xevo, NIST, University of Michigan, Institute, Pharmaceutics, Waters Corporation, Carnegie Mellon University, Education, Commerce, Mass spectrometry, National Institute, U.S. Department of Defense Strategy for Operating in Cyberspace, University of Georgia, Delaware, University of Delaware, Project, Government, Industry, NIPTE, Fine chemical, Vaccine, Electronic component

To date, NIIMBL has now funded over 86 technical, workforce development, and Global Health projects with a total investment of approximately $72M since 2017 when the Institute launched.

Key Points: 
  • To date, NIIMBL has now funded over 86 technical, workforce development, and Global Health projects with a total investment of approximately $72M since 2017 when the Institute launched.
  • The NIIMBL community is comprised of more than 180 members from academia, industry, government and non-profit organizations all sharing a common goal to advance biopharmaceutical manufacturing.
  • For a description of each project and to learn more about NIIMBL, please visit the Project Call 5.1 website .
  • The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.

American Pharmaceutical Review Releases Documentary on Continuous Pharmaceutical Manufacturing

Retrieved on: 
Wednesday, May 9, 2018
Health, Pharmacy, Pharmacology, Pharmaceutical industry, Pharmaceutical industry in China, Pharmaceuticals policy, Science and technology in the People's Republic of China, Pharmaceutics, NIPTE

SOUTH SAN FRANCISCO, Calif., May 9, 2018 /PRNewswire/ --American Pharmaceutical Review, the leading review of business and technology for the pharmaceutical industry throughout North America has released its documentary on "Continuous Pharmaceutical Manufacturing - Current Trends and Future Possibilities".

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 9, 2018 /PRNewswire/ --American Pharmaceutical Review, the leading review of business and technology for the pharmaceutical industry throughout North America has released its documentary on "Continuous Pharmaceutical Manufacturing - Current Trends and Future Possibilities".
  • The goal of the documentary is to examine the future role continuous manufacturing will take in the production of both large and small molecule pharmaceuticals.
  • "While many other manufacturing industries have moved to, or are in the process of adopting a continuous manufacturing paradigm, the pharmaceutical industry is just beginning to explore the possibilities of moving from traditional batch-based manufacturing processes to a more continuous, and some might argue efficient process," says Mike Auerbach, Editor In Chief, American Pharmaceutical Review.
  • American Pharmaceutical Review is the leading journal for business and technology in the pharmaceutical industry.